2025 Q3 -tulosraportti
74 päivää sitten28 min
Tarjoustasot
First North Sweden
Määrä
Osto
1 785
Myynti
Määrä
163 232
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 1 785 | - | - | ||
| 9 475 | - | - | ||
| 710 | - | - | ||
| 1 153 | - | - | ||
| 50 | - | - |
Ylin
0,262VWAP
Alin
0,255VaihtoMäärä
0,1 568 809
VWAP
Ylin
0,262Alin
0,255VaihtoMäärä
0,1 568 809
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
| 2025 Q4 -tulosraportti | 12.2. |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3 -tulosraportti | 6.11.2025 | |
| 2025 Q2 -tulosraportti | 21.8.2025 | |
| 2025 Q1 -tulosraportti | 12.5.2025 | |
| 2024 Q4 -tulosraportti | 13.2.2025 | |
| 2024 Q3 -tulosraportti | 7.11.2024 |
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·3 päivää sittenI don't understand the continuous decline when the company is doing so well📉·2 päivää sittenIt's perhaps just because you are long in this stock.we have switched to not sending out announcements about just anything. Yes, it has fallen, but these are just small micro trades happening all the time, compared to the volume of shares nothing is happening. Use it to lower the average if one can. There are plenty of good opportunities ahead, we are just impatient, perhaps because everyone...or most can see the potential in this stock. Yes, it falls on the small trades, those who hoped for a small profit, drop it again. I am long and I have many, so many that I cannot just get rid of them easily. So I sit and wait, patiently. It's a bit like banks, it's so conservative and takes a long time to change habits in this industry, and for us it just can't go fast enough. Hold on, would be my advice.- ·2.1.Long text, but valuable if you don't have time to research yourself: Who are the people sharing Acarix on LinkedIn and why are they relevant? 1. Waleed (cardiologist / consultant) He is a practicing cardiologist and shares content about CADScor’ even in Arabic. It is important because: • It's a clinician, not marketing • He shows real use and understanding of the product • It points towards the MENA region (Middle East), which Acarix itself has mentioned as a growth area In short: The product is being picked up by doctors outside the “Acarix bubble”. 2. Ken Nelson (board member – MedTech Leader of the Year) Ken Nelson is not just anyone: • Many years of experience from American MedTech • Has been involved in scaling, reimbursement, and exits • Sits on the board, not employed in marketing When he reposts Acarix content, it's a signal that: • He stands behind the direction • He actively uses his network • The kind of “quiet legitimacy” is being built, which often precedes major breakthroughs in the USA 3. Chris Kimberly (Valuation Analyst, HMS Valuation Partners) An underestimated, but important profile: • Works professionally with healthcare and MedTech valuation • His work is specifically to assess what technologies are worth in the healthcare system • When he likes, comments, or shares, it's not retail-hype It doesn't mean “price target tomorrow”, but it means that Acarix is on the radar of people who work with valuation and reimbursement. 4. Dr. Niels Jacobsohn Academic profile with a focus on cardiovascular diseases. When he shares Acarix content, it emphasizes: • Scientific legitimacy • Professional relevance over advertising 5. Aamir Mahmood – CEO His posts are about, among other things: • Rural Health funding • JPM Healthcare Conference 2026 • Clinical results (0 heart attacks in follow-up) It's not hype, but: • Positioning before decisions • Visibility towards investors, partners, and healthcare systems • Classic signal that one is ready and fits into what is coming CEOs rarely post randomly, especially leading up to JPM. What does it mean overall? The important thing is not one post in isolation, but the pattern: • Clinical doctors share the product • Board members activate networks • Valuation profiles engage • CEO speaks directly into current funding and structural changes • Focus is on prevention, reimbursement, rural health, and scalability These are precisely the themes that drive real adoption, not press releases alone. Honestly This doesn't look like “pump”. It looks like long-term, American MedTech positioning, where: • The product already works • The documentation is there • The systems are slowly shifting The market often reacts late to this kind of thing. First come relationships, acceptance, and structure, the price comes afterwards. Therefore, many also feel that “it doesn't make sense that it hasn't risen more yet”. The foundation is often built long before the price reflects it.
·3.1. · MuokattuGood summary 👍🙂. But Waleed is guaranteed to be more than just a cardiologist and clinician. He has contact with the Minister of Health, with whom he has had a meeting, and will also hold a training session on how to use cadscore. He's worth looking into a bit more. He probably has more than one finger in the pie regarding the rollout of cadscor in Iraq and the Middle East. 
·31.12.2025I have followed some who predict this stock will become a growth stock in 2026 - is it a good entry point to buy into it at the current price? Happy New Year to all 🎇
·4.1.Where do you think the price will be in 2027? And 2030?
·31.12.2025People always underestimate how long it takes and haven't been in the USA for that long. We are now seeing the increase of CS-consignment in the USA in a good way… looks like it will become self-sustaining by 2026 at the very least. Several important cornerstones were established in the USA at the end of summer. I'm becoming more and more doubtful about RHT, even though it would have been a good bonus-accelerator. MENA, however, could probably become a major market.. a different view than Sweden and Germany, very positive signals from there so far!! RE went smoothly and practically without discount, a very good sign. Not to mention Aamir's work, own ownership & 100% commitment! People are impatient but now that it actually starts to look genuinely promising, they sulk…?! Very strange.·2.1.Aamir just liked Virginia's post about RHTP today, which of course makes one curious then!! Found Virginia's (considering Aamir's like) application now (was not public before, cannot find newer documents that they have written anything specific about grants yet), it is a bit more concise than other states': https://wvpublic.org/wp-content/uploads/2025/11/FINAL_West_Virginia_Rural_Health_Transformation.pdf Anyway, there you can actually find something that could include CADScor! ”Groundbreaking healthcare technologies Finally, West Virginia’s Rural Health Transformation will fund the development and commercialization of new healthcare technologies. The program’s HealthTech Appalachia initiative will invest—along with private partners—in technologies that address chronic disease and addiction and that promote personal wellness. Successful technologies will not only improve healthcare in West Virginia and around the country but will jumpstart the technology sector in the state’s economy.” Looked up: HealthTech Appalachia refers to the intersection of health technology and healthcare innovation in the Appalachian region, addressing significant health disparities through initiatives like telehealth, mobile clinics eg., The Health Wagon which I in turn looked up a bit: ”Central Appalachia residents present unique healthcare challenges. This vulnerable population faces poor health status and low access to health care. 'The Health Wagon' was established to innovatively enhance access to health care for the poor and marginalized rural population of Central Appalachia. This article describes the operations of the Health Wagon, a full mobile medical clinic, in delivering free health care to those in rural Southwest Virginia in Central Appalachia. The Health Wagon provides a wide range of comprehensive healthcare services, such as acute and chronic disease management” That sounds like a job for CADScor!
·30.12.2025What happened to the rocket? Come on, many believed this one would be much higher in price than is the case. It has really become a dead stock, like so many other small Swedish biotech companies where so much is promised by management and so little is kept and achieved. Ugh ugh.·31.12.2025People always underestimate how long it takes and haven't been in the USA for that long. We are seeing the increase in CS-consignment in the USA now in a good way… looks like it will become self-sustaining by 2026 at the very least. Several important cornerstones were established in the USA at the end of summer. I am becoming more and more doubtful about RHT, even though it would have been a good bonus-accelerator. MENA, however, could probably become a major market… a different view than Sweden and Germany, very positive signals from there so far!!
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q3 -tulosraportti
74 päivää sitten28 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·3 päivää sittenI don't understand the continuous decline when the company is doing so well📉·2 päivää sittenIt's perhaps just because you are long in this stock.we have switched to not sending out announcements about just anything. Yes, it has fallen, but these are just small micro trades happening all the time, compared to the volume of shares nothing is happening. Use it to lower the average if one can. There are plenty of good opportunities ahead, we are just impatient, perhaps because everyone...or most can see the potential in this stock. Yes, it falls on the small trades, those who hoped for a small profit, drop it again. I am long and I have many, so many that I cannot just get rid of them easily. So I sit and wait, patiently. It's a bit like banks, it's so conservative and takes a long time to change habits in this industry, and for us it just can't go fast enough. Hold on, would be my advice.
- ·2.1.Long text, but valuable if you don't have time to research yourself: Who are the people sharing Acarix on LinkedIn and why are they relevant? 1. Waleed (cardiologist / consultant) He is a practicing cardiologist and shares content about CADScor’ even in Arabic. It is important because: • It's a clinician, not marketing • He shows real use and understanding of the product • It points towards the MENA region (Middle East), which Acarix itself has mentioned as a growth area In short: The product is being picked up by doctors outside the “Acarix bubble”. 2. Ken Nelson (board member – MedTech Leader of the Year) Ken Nelson is not just anyone: • Many years of experience from American MedTech • Has been involved in scaling, reimbursement, and exits • Sits on the board, not employed in marketing When he reposts Acarix content, it's a signal that: • He stands behind the direction • He actively uses his network • The kind of “quiet legitimacy” is being built, which often precedes major breakthroughs in the USA 3. Chris Kimberly (Valuation Analyst, HMS Valuation Partners) An underestimated, but important profile: • Works professionally with healthcare and MedTech valuation • His work is specifically to assess what technologies are worth in the healthcare system • When he likes, comments, or shares, it's not retail-hype It doesn't mean “price target tomorrow”, but it means that Acarix is on the radar of people who work with valuation and reimbursement. 4. Dr. Niels Jacobsohn Academic profile with a focus on cardiovascular diseases. When he shares Acarix content, it emphasizes: • Scientific legitimacy • Professional relevance over advertising 5. Aamir Mahmood – CEO His posts are about, among other things: • Rural Health funding • JPM Healthcare Conference 2026 • Clinical results (0 heart attacks in follow-up) It's not hype, but: • Positioning before decisions • Visibility towards investors, partners, and healthcare systems • Classic signal that one is ready and fits into what is coming CEOs rarely post randomly, especially leading up to JPM. What does it mean overall? The important thing is not one post in isolation, but the pattern: • Clinical doctors share the product • Board members activate networks • Valuation profiles engage • CEO speaks directly into current funding and structural changes • Focus is on prevention, reimbursement, rural health, and scalability These are precisely the themes that drive real adoption, not press releases alone. Honestly This doesn't look like “pump”. It looks like long-term, American MedTech positioning, where: • The product already works • The documentation is there • The systems are slowly shifting The market often reacts late to this kind of thing. First come relationships, acceptance, and structure, the price comes afterwards. Therefore, many also feel that “it doesn't make sense that it hasn't risen more yet”. The foundation is often built long before the price reflects it.·3.1. · MuokattuGood summary 👍🙂. But Waleed is guaranteed to be more than just a cardiologist and clinician. He has contact with the Minister of Health, with whom he has had a meeting, and will also hold a training session on how to use cadscore. He's worth looking into a bit more. He probably has more than one finger in the pie regarding the rollout of cadscor in Iraq and the Middle East.
- ·31.12.2025I have followed some who predict this stock will become a growth stock in 2026 - is it a good entry point to buy into it at the current price? Happy New Year to all 🎇·4.1.Where do you think the price will be in 2027? And 2030?
- ·31.12.2025People always underestimate how long it takes and haven't been in the USA for that long. We are now seeing the increase of CS-consignment in the USA in a good way… looks like it will become self-sustaining by 2026 at the very least. Several important cornerstones were established in the USA at the end of summer. I'm becoming more and more doubtful about RHT, even though it would have been a good bonus-accelerator. MENA, however, could probably become a major market.. a different view than Sweden and Germany, very positive signals from there so far!! RE went smoothly and practically without discount, a very good sign. Not to mention Aamir's work, own ownership & 100% commitment! People are impatient but now that it actually starts to look genuinely promising, they sulk…?! Very strange.·2.1.Aamir just liked Virginia's post about RHTP today, which of course makes one curious then!! Found Virginia's (considering Aamir's like) application now (was not public before, cannot find newer documents that they have written anything specific about grants yet), it is a bit more concise than other states': https://wvpublic.org/wp-content/uploads/2025/11/FINAL_West_Virginia_Rural_Health_Transformation.pdf Anyway, there you can actually find something that could include CADScor! ”Groundbreaking healthcare technologies Finally, West Virginia’s Rural Health Transformation will fund the development and commercialization of new healthcare technologies. The program’s HealthTech Appalachia initiative will invest—along with private partners—in technologies that address chronic disease and addiction and that promote personal wellness. Successful technologies will not only improve healthcare in West Virginia and around the country but will jumpstart the technology sector in the state’s economy.” Looked up: HealthTech Appalachia refers to the intersection of health technology and healthcare innovation in the Appalachian region, addressing significant health disparities through initiatives like telehealth, mobile clinics eg., The Health Wagon which I in turn looked up a bit: ”Central Appalachia residents present unique healthcare challenges. This vulnerable population faces poor health status and low access to health care. 'The Health Wagon' was established to innovatively enhance access to health care for the poor and marginalized rural population of Central Appalachia. This article describes the operations of the Health Wagon, a full mobile medical clinic, in delivering free health care to those in rural Southwest Virginia in Central Appalachia. The Health Wagon provides a wide range of comprehensive healthcare services, such as acute and chronic disease management” That sounds like a job for CADScor!
- ·30.12.2025What happened to the rocket? Come on, many believed this one would be much higher in price than is the case. It has really become a dead stock, like so many other small Swedish biotech companies where so much is promised by management and so little is kept and achieved. Ugh ugh.·31.12.2025People always underestimate how long it takes and haven't been in the USA for that long. We are seeing the increase in CS-consignment in the USA now in a good way… looks like it will become self-sustaining by 2026 at the very least. Several important cornerstones were established in the USA at the end of summer. I am becoming more and more doubtful about RHT, even though it would have been a good bonus-accelerator. MENA, however, could probably become a major market… a different view than Sweden and Germany, very positive signals from there so far!!
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
First North Sweden
Määrä
Osto
1 785
Myynti
Määrä
163 232
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 1 785 | - | - | ||
| 9 475 | - | - | ||
| 710 | - | - | ||
| 1 153 | - | - | ||
| 50 | - | - |
Ylin
0,262VWAP
Alin
0,255VaihtoMäärä
0,1 568 809
VWAP
Ylin
0,262Alin
0,255VaihtoMäärä
0,1 568 809
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
| 2025 Q4 -tulosraportti | 12.2. |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3 -tulosraportti | 6.11.2025 | |
| 2025 Q2 -tulosraportti | 21.8.2025 | |
| 2025 Q1 -tulosraportti | 12.5.2025 | |
| 2024 Q4 -tulosraportti | 13.2.2025 | |
| 2024 Q3 -tulosraportti | 7.11.2024 |
2025 Q3 -tulosraportti
74 päivää sitten28 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
| 2025 Q4 -tulosraportti | 12.2. |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3 -tulosraportti | 6.11.2025 | |
| 2025 Q2 -tulosraportti | 21.8.2025 | |
| 2025 Q1 -tulosraportti | 12.5.2025 | |
| 2024 Q4 -tulosraportti | 13.2.2025 | |
| 2024 Q3 -tulosraportti | 7.11.2024 |
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·3 päivää sittenI don't understand the continuous decline when the company is doing so well📉·2 päivää sittenIt's perhaps just because you are long in this stock.we have switched to not sending out announcements about just anything. Yes, it has fallen, but these are just small micro trades happening all the time, compared to the volume of shares nothing is happening. Use it to lower the average if one can. There are plenty of good opportunities ahead, we are just impatient, perhaps because everyone...or most can see the potential in this stock. Yes, it falls on the small trades, those who hoped for a small profit, drop it again. I am long and I have many, so many that I cannot just get rid of them easily. So I sit and wait, patiently. It's a bit like banks, it's so conservative and takes a long time to change habits in this industry, and for us it just can't go fast enough. Hold on, would be my advice.
- ·2.1.Long text, but valuable if you don't have time to research yourself: Who are the people sharing Acarix on LinkedIn and why are they relevant? 1. Waleed (cardiologist / consultant) He is a practicing cardiologist and shares content about CADScor’ even in Arabic. It is important because: • It's a clinician, not marketing • He shows real use and understanding of the product • It points towards the MENA region (Middle East), which Acarix itself has mentioned as a growth area In short: The product is being picked up by doctors outside the “Acarix bubble”. 2. Ken Nelson (board member – MedTech Leader of the Year) Ken Nelson is not just anyone: • Many years of experience from American MedTech • Has been involved in scaling, reimbursement, and exits • Sits on the board, not employed in marketing When he reposts Acarix content, it's a signal that: • He stands behind the direction • He actively uses his network • The kind of “quiet legitimacy” is being built, which often precedes major breakthroughs in the USA 3. Chris Kimberly (Valuation Analyst, HMS Valuation Partners) An underestimated, but important profile: • Works professionally with healthcare and MedTech valuation • His work is specifically to assess what technologies are worth in the healthcare system • When he likes, comments, or shares, it's not retail-hype It doesn't mean “price target tomorrow”, but it means that Acarix is on the radar of people who work with valuation and reimbursement. 4. Dr. Niels Jacobsohn Academic profile with a focus on cardiovascular diseases. When he shares Acarix content, it emphasizes: • Scientific legitimacy • Professional relevance over advertising 5. Aamir Mahmood – CEO His posts are about, among other things: • Rural Health funding • JPM Healthcare Conference 2026 • Clinical results (0 heart attacks in follow-up) It's not hype, but: • Positioning before decisions • Visibility towards investors, partners, and healthcare systems • Classic signal that one is ready and fits into what is coming CEOs rarely post randomly, especially leading up to JPM. What does it mean overall? The important thing is not one post in isolation, but the pattern: • Clinical doctors share the product • Board members activate networks • Valuation profiles engage • CEO speaks directly into current funding and structural changes • Focus is on prevention, reimbursement, rural health, and scalability These are precisely the themes that drive real adoption, not press releases alone. Honestly This doesn't look like “pump”. It looks like long-term, American MedTech positioning, where: • The product already works • The documentation is there • The systems are slowly shifting The market often reacts late to this kind of thing. First come relationships, acceptance, and structure, the price comes afterwards. Therefore, many also feel that “it doesn't make sense that it hasn't risen more yet”. The foundation is often built long before the price reflects it.·3.1. · MuokattuGood summary 👍🙂. But Waleed is guaranteed to be more than just a cardiologist and clinician. He has contact with the Minister of Health, with whom he has had a meeting, and will also hold a training session on how to use cadscore. He's worth looking into a bit more. He probably has more than one finger in the pie regarding the rollout of cadscor in Iraq and the Middle East.
- ·31.12.2025I have followed some who predict this stock will become a growth stock in 2026 - is it a good entry point to buy into it at the current price? Happy New Year to all 🎇·4.1.Where do you think the price will be in 2027? And 2030?
- ·31.12.2025People always underestimate how long it takes and haven't been in the USA for that long. We are now seeing the increase of CS-consignment in the USA in a good way… looks like it will become self-sustaining by 2026 at the very least. Several important cornerstones were established in the USA at the end of summer. I'm becoming more and more doubtful about RHT, even though it would have been a good bonus-accelerator. MENA, however, could probably become a major market.. a different view than Sweden and Germany, very positive signals from there so far!! RE went smoothly and practically without discount, a very good sign. Not to mention Aamir's work, own ownership & 100% commitment! People are impatient but now that it actually starts to look genuinely promising, they sulk…?! Very strange.·2.1.Aamir just liked Virginia's post about RHTP today, which of course makes one curious then!! Found Virginia's (considering Aamir's like) application now (was not public before, cannot find newer documents that they have written anything specific about grants yet), it is a bit more concise than other states': https://wvpublic.org/wp-content/uploads/2025/11/FINAL_West_Virginia_Rural_Health_Transformation.pdf Anyway, there you can actually find something that could include CADScor! ”Groundbreaking healthcare technologies Finally, West Virginia’s Rural Health Transformation will fund the development and commercialization of new healthcare technologies. The program’s HealthTech Appalachia initiative will invest—along with private partners—in technologies that address chronic disease and addiction and that promote personal wellness. Successful technologies will not only improve healthcare in West Virginia and around the country but will jumpstart the technology sector in the state’s economy.” Looked up: HealthTech Appalachia refers to the intersection of health technology and healthcare innovation in the Appalachian region, addressing significant health disparities through initiatives like telehealth, mobile clinics eg., The Health Wagon which I in turn looked up a bit: ”Central Appalachia residents present unique healthcare challenges. This vulnerable population faces poor health status and low access to health care. 'The Health Wagon' was established to innovatively enhance access to health care for the poor and marginalized rural population of Central Appalachia. This article describes the operations of the Health Wagon, a full mobile medical clinic, in delivering free health care to those in rural Southwest Virginia in Central Appalachia. The Health Wagon provides a wide range of comprehensive healthcare services, such as acute and chronic disease management” That sounds like a job for CADScor!
- ·30.12.2025What happened to the rocket? Come on, many believed this one would be much higher in price than is the case. It has really become a dead stock, like so many other small Swedish biotech companies where so much is promised by management and so little is kept and achieved. Ugh ugh.·31.12.2025People always underestimate how long it takes and haven't been in the USA for that long. We are seeing the increase in CS-consignment in the USA now in a good way… looks like it will become self-sustaining by 2026 at the very least. Several important cornerstones were established in the USA at the end of summer. I am becoming more and more doubtful about RHT, even though it would have been a good bonus-accelerator. MENA, however, could probably become a major market… a different view than Sweden and Germany, very positive signals from there so far!!
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
First North Sweden
Määrä
Osto
1 785
Myynti
Määrä
163 232
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 1 785 | - | - | ||
| 9 475 | - | - | ||
| 710 | - | - | ||
| 1 153 | - | - | ||
| 50 | - | - |
Ylin
0,262VWAP
Alin
0,255VaihtoMäärä
0,1 568 809
VWAP
Ylin
0,262Alin
0,255VaihtoMäärä
0,1 568 809
Välittäjätilasto
Dataa ei löytynyt